A5102750154- Lipoproteins and Cardiovascular Health
- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Pharmaceutical Economics and Policy
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Acute Myocardial Infarction Research
- Statistical Methods in Clinical Trials
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Atrial Fibrillation Management and Outcomes
- Diet and metabolism studies
- Venous Thromboembolism Diagnosis and Management
- Drug Transport and Resistance Mechanisms
- Cardiovascular Function and Risk Factors
- GDF15 and Related Biomarkers
- Cardiomyopathy and Myosin Studies
- Bone and Joint Diseases
- Autophagy in Disease and Therapy
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Cardiac Imaging and Diagnostics
Eli Lilly (United States)
2006-2022
Indianapolis Zoo
2003
Murphy Oil Corporation (United States)
1989
The University of Texas Health Science Center at San Antonio
1989
To better understand the marked decrease in serum triglycerides observed with tirzepatide patients type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc available samples from same study.Patients randomized to receive once-weekly subcutaneous (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) placebo. Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III preheparin lipase (LPL) at baseline 4, 12 26 weeks. Lipoprotein particle profile by nuclear magnetic...
Although lipoprotein(a) (Lp[a]) is a causal genetic risk factor for atherosclerotic cardiovascular disease, it remains unclear which patients with established disease stand to benefit the most from Lp(a) lowering. Whether inflammation can modulate Lp(a)-associated (CV) during secondary prevention unknown.To examine whether CV modulated by systemic in optimally treated at high of disease.A prespecified post hoc analysis double-blind, multicenter randomized clinical Assessment Clinical Effects...
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, US Food and Drug Administration Committee Medicinal Products Human Use European Medicines Agency issued guidance pharmaceutical industry in 2008. Glucose-lowering therapies were granted regulatory approval primarily from smaller studies that have demonstrated reductions glycated hemoglobin concentration. Such...
Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate safety prasugrel, a thienopyridine agent, adult patients with SCD, we conducted double-blind, randomized, placebo-controlled study. The primary endpoint, safety, was measured by hemorrhagic events requiring medical intervention. Patients were randomized to prasugrel 5 mg daily (n = 41) or placebo 21) for 30 days. function VerifyNow® P2Y12 and...
In TRITON-TIMI 38, levels of the prasugrel active metabolite (pras-AM) were measured in a population pharmacokinetic substudy that characterized intrinsic and extrinsic factors influencing exposure. Higher exposure to pras-AM was observed low-weight or very elderly patients. The authors hypothesized this higher might explain risk non-coronary artery bypass graft (CABG)-related TIMI-related bleeding these 2 patient populations. relationship between estimated clinical outcomes assessed 1159...
A pharmacogenetic analysis of dalcetrapib, a cholesteryl ester transfer protein inhibitor, reported an association between single-nucleotide polymorphism (SNP) in the ADCY9 gene (rs1967309) and reduction major adverse cardiovascular events despite neutral result for overall trial.To determine whether SNP could be replicated another evacetrapib, patients with high-risk vascular disease.A nested case-control study examining rs1967309 1427 cases 1532 matched controls selected from 12...
To examine the generalizability of results from glucagon-like peptide-1 receptor agonist (GLP-1 RA) cardiovascular outcome trials (CVOTs) in US type 2 diabetes (T2D) population.Patients enrolled or eligible for inclusion four CVOTs (EXSCEL, LEADER, REWIND, and SUSTAIN-6) were examined reference to a retrospective clinical database weighted match age sex distribution adult T2D population. We descriptively compared key baseline characteristics populations each trial those population estimated...
Background The contemporary impact of glycemic control on patients with diabetes mellitus at high cardiovascular risk remains unclear. We evaluated the utility hemoglobin A1c (HbA1c) as a marker composite end point death, nonfatal myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization in an optimally treated population established artery disease enrolled ACCELERATE (Assessment Clinical Effects Cholesteryl Ester Transfer Protein Inhibition With...
Background: Despite optimal treatment, type II diabetes mellitus remains associated with an increased risk for future cardiovascular events. We sought to determine the association between baseline fasting plasma insulin levels and major adverse outcomes in patients high-risk vascular disease enrolled ACCELERATE (Assessment of Clinical Effects Cholesteryl Ester Transfer Protein Inhibition Evacetrapib Patients at a High Risk Vascular Outcomes) trial. Methods: included all who had central...
Background Efficacy and safety of novel dual GIP/GLP-1 receptor agonist tirzepatide versus insulin glargine was assessed in adults with type 2 diabetes inadequately controlled on metformin, sulfonylurea, and/or SGLT-2i increased cardiovascular risk.
Outcomes in patients with acute myocardial infarction (AMI) who received adjunctive therapy glycoprotein (GP) IIb/IIIa-receptor inhibitors during percutaneous coronary intervention (PCI) were studied. Data from a national all-payer database for the period January 2000 to July 2001 analyzed compare in-hospital mortality, complications, incremental costs, and length of stay between AMI did not receive GP inhibitor PCI. Risk adjustment was performed by logistic regression account differences...
Background:Inhibition of cholesteryl ester transfer protein with evacetrapib may provide an additional treatment option for patients who do not reach their low-density lipoprotein cholesterol (LDL-C) goal statins or cannot tolerate statins.
Inhibition of cholesteryl ester transfer protein by evacetrapib when added to atorvastatin may provide an additional treatment option for patients who do not reach their low-density lipoprotein cholesterol (LDL-C) goal.Methods and Results:This multicenter, randomized, 12-week, double-blind, parallel-group, placebo-controlled, outpatient, phase 3 study evaluated the efficacy with in reducing LDL-C 149 Japanese (evacetrapib/atorvastatin, n=53; ezetimibe/atorvastatin, n=50;...